These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15788209)

  • 1. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
    Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
    Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
    Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
    Hsu WC; Chan SC; Ting LL; Chung NN; Wang PM; Ying KS; Shin JS; Chao CJ; Lin GD
    Jpn J Clin Oncol; 2006 Feb; 36(2):93-9. PubMed ID: 16517834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis.
    Wen J; Shen WL; Yang SH
    Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):224-7. PubMed ID: 16698580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
    Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
    Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
    Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
    Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ; Malya R; Rawat A
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
    Cipriani G; Mazzanti R
    Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
    [No Abstract]   [Full Text] [Related]  

  • 14. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
    Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
    Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
    Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.
    Villa E; Ferretti I; Grottola A; Buttafoco P; Buono MG; Giannini F; Manno M; Bertani H; Dugani A; Manenti F
    Br J Cancer; 2001 Apr; 84(7):881-5. PubMed ID: 11286465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
    Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
    Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
    Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
    Ch'ang HJ; Hsu C; Chen CH; Chang YH; Chang JS; Chen LT
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):817-25. PubMed ID: 21277098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.